Biomarker Identification and Pathway Analysis by Serum Metabolomics of Lung Cancer

Table 1

LC-Q-TOF/MS identification of potential serum biomarkers in lung cancer.

Number	Retention time (min)	m/z	Metabolites	Relative mass intensity
				Control group	Preoperative lung cancer group (PRLC)	Postoperative lung cancer group (POLC)
1	9.47	368.1655	Prasterone sulfate	106.80 ± 31.70	71.99 ± 38.72^*	50.93 ± 22.26^*
2	11.89	299.2816	Sphingosine	139.60 ± 38.75	53.33 ± 35.95^*#	141.78 ± 42.42
3	12.17	169.0481	Phosphorylcholine	72.70 ± 14.16	133.28 ± 75.49^*#	82.17 ± 28.31
4	13.06	501.2862	Glycerophospho-N-arachidonoyl ethanolamine	1355.53 ± 282.89	2722.76 ± 769.63^*#	1714.79 ± 399.47
5	16.06	278.2241	γ-Linolenic acid	500.34 ± 204.80	1245.99 ± 595.41^*#	602.06 ± 226.28

 ^*Compared with control group, ; ^#compared with postoperative lung cancer group, .